Safety of Arthritis Drugs, Day 3. Part 4
Dr. Wood is chairman of the Arthritis Advisory Committee, Drug Safety and Risk Management Committee.
This is the last day of a joint meeting of the FDA’s Arthritis and Drug Safety and Risk Management Advisory Committees. At the end of the th… read more
This is the last day of a joint meeting of the FDA’s Arthritis and Drug Safety and Risk Management Advisory Committees. At the end of the three-day forum the 32-member panel had recommended that arthritis drugs Celebrex and Bextra stay on the market with restrictions. This portion included the 17-15 vote that Vioxx should stay on the U.S. market, and other votes about restrictions on Vioxx.
Dr. Wood is chairman of the Arthritis Advisory Committee, Drug Safety and Risk Management Committee. close
People in this video
More PeopleHosting Organization
More Videos From
Safety of Arthritis Drugs, Day 3,
More VideosRelated Video
-
Food and Drug Administration Approval Process
The House Government Reform Committee held a hearing on the Food and Drug Administration’s approval process for pharmace…
-
Presidential Radio Address
In his weekly radio address President Bush talked about the May 15 deadline for signing up for the new Medicare prescrip…
-
Drug Approval Process
William Hubbard talked about prescription drug safety and the Food and Drug Administration’s drug approval process. The …
-
The Vioxx Settlement
A panel discussion was held about the settlement Merck made with users of its pain reliever Vioxx, which it withdrew fro…